4 research outputs found
Enflasyon hedeflemesi rejimi: Türkiye örneği
Bu çalışmada enflasyon hedeflemesi rejimi en temel kavramları ile aktarılmış olup,
Türkiye’nin gelişmiş ve diğer gelişmekte olan ülkeler ile karşılaştırılması yapılmaya
çalışılmıştır. İlk bölümde genel olarak para politikalarından bahsedilmiştir. Enflasyon
hedeflemesi rejimi politikasını açıklamak adına avantaj ve dezavantajları gösterilmektedir.
Makalenin ikinci bölümünde ise gelişmiş ve gelişmekte olan ülkelerin enflasyon
hedeflemesi rejimi tarihlerine değinilmiş olup rejimin enflasyon oranları üzerindeki etkileri
ele alınmıştır. Üçüncü bölüme gelindiğinde ise Türkiye’nin enflasyon tarihi ele alınmış ve
2002-2005 yıllarında örtük enflasyon hedeflemesi ile geçiş yaptığı enflasyon hedeflemesi
rejiminden sonraki enflasyonist sürecine vurgu yapılmıştır. Genel değerlendirme
çerçevesinde ise Türkiye’nin enflasyon hedeflemesi uygulamasında başarıya ulaşıp
ulaşmadığı değerlendirilmiştir
MOTHERS OF AUTOSOMAL RECESSIVE CHRONIC GRANULOMATOUS DISEASE PATIENTS DO NOT SHOW AUTOIMMUNE FINDINGS IN CONTRAST TO X-LINKED PATIENTS
Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016
Background/Aims: To evaluate the HCV RNA genotyping and HDV RNA tests that are performed in molecular microbiology laboratories in Turkey as part of a national external quality assessment programme, MOTAKK (Molekuler Tanida Kalite Kontrol) (English translation: Quality control in molecular diagnostics)
Re-examining the characteristics of pediatric multiple sclerosis in the era of antibody-associated demyelinating syndromes.
Background: The discovery of anti-myelin oligodendrocyte glycoprotein (MOG)-IgG and anti-aquaporin 4 (AQP4)-IgG and the observation on certain patients previously diagnosed with multiple sclerosis (MS) actually have an antibody-mediated disease mandated re-evaluation of pediatric MS series. Aim: To describe the characteristics of recent pediatric MS cases by age groups and compare with the cohort established before 2015. Method: Data of pediatric MS patients diagnosed between 2015 and 2021 were collected from 44 pediatric neurology centers across Turkiye. Clinical and paraclinical features were compared between patients with dis-ease onset before 12 years (earlier onset) and >= 12 years (later onset) as well as between our current (2015-2021) and previous (< 2015) cohorts. Results: A total of 634 children (456 girls) were enrolled, 89 (14%) were of earlier onset. The earlier-onset group had lower female/male ratio, more frequent initial diagnosis of acute disseminated encephalomyelitis (ADEM), more frequent brainstem symptoms, longer interval between the first two attacks, less frequent spinal cord involvement on magnetic resonance imaging (MRI), and lower prevalence of cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCBs). The earlier-onset group was less likely to respond to initial disease-modifying treatments. Compared to our previous cohort, the current series had fewer patients with onset < 12 years, initial presentation with ADEM-like features, brainstem or cerebellar symptoms, seizures, and spinal lesions on MRI. The female/male ratio, the frequency of sensorial symptoms, and CSF-restricted OCBs were higher than reported in our previous cohort. Conclusion: Pediatric MS starting before 12 years was less common than reported previously, likely due to exclusion of patients with antibody-mediated diseases. The results underline the importance of antibody testing and indicate pediatric MS may be a more homogeneous disorder and more similar to adult-onset MS than previously thought